Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIALE-M: Venetoclax and Azacitidine as Maintenance Therapy in AML First Remission
2023-507221-42-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3 trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by AbbVie Inc. Started Feb 2024; status: completed.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-507221-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507221-42-00.